Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan

Background Tocilizumab (TCZ), an interleukin-6 (IL-6) receptor blocker, emerged as a treatment for cytokine release syndrome (CRS) in patients with severe COVID-19 pneumonia. The main objective of the study is to discuss the treatment response of TCZ in severe and critically ill patients with COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Muhammad, Syed, Fibhaa, Zafar, Maria, Iqbal, Mansoor, Khan, Naveed Ullah, Mushtaq, Hafiza Faiza, Badshah, Mazhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729311/
https://www.ncbi.nlm.nih.gov/pubmed/35004038
http://dx.doi.org/10.7759/cureus.20219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729311/
https://www.ncbi.nlm.nih.gov/pubmed/35004038
http://dx.doi.org/10.7759/cureus.20219

Ejemplares similares